Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies
CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead



BiotechTV - News